THIO sequenced with Libtayo prolonged OS in NSCLC following development. | © steph photographies – inventory.adobe.com
Therapy with the lead medical candidate THIO (6-thio-dG or 6-thio-2’-deoxyguanosine) sequenced with the checkpoint inhibitor Libtayo (cemiplimab) prolonged general survival (OS) in sufferers with superior non–small cell lung most cancers (NSCLC) who progressed on two or extra standard-of-care remedy regimens, in accordance with up to date information from the pivotal section 2 THIO-101 medical trial which have been shared in a press launch from MAIA Biotechnology, Inc.
The third-line information confirmed a median OS of 16.9 months as of Jan. 15, 2025, in sufferers with NSCLC (22 sufferers) who have been handled with at the least one dose of THIO; these have been sufferers within the intent-to- deal with inhabitants who have been included in components A and B of the trial. This demonstrated an enchancment in OS in contrast with the five-to-six-month OS that has been noticed with standard-of-care chemotherapy remedies in NSCLC in an identical setting.
Glossary
General survival (OS): the size of time a affected person lives after being recognized with most cancers.
General response fee (ORR): the share of sufferers who expertise a partial or full response to a most cancers remedy.
“Therapy with THIO now reveals a 99% likelihood that general survival will lengthen previous chemotherapy’s measure by a large margin,” Dr. Vlad Vitoc, chief govt officer of MAIA, mentioned within the press launch. “THIO’s efficacy in superior levels of NSCLC continues to exceed our expectations, particularly in third-line remedy the place the most cancers is usually much more proof against remedy. Our findings counsel nice advantages to sufferers with unmet medical wants who see little hope for the longer term.”
The corporate believes that, primarily based on the regulatory technique, there could also be a possibility for an accelerated Meals and Drug Administration (FDA) approval for remedy with THIO, pending last outcomes from the continuing growth of the THIO-101 trial, in accordance with the press launch.
Extra on The Investigative Agent and Part 2 Trial
THIO is a first-in-class investigational agent which was designed to focus on telomeres, that are essential for most cancers cell survival and resistance to present therapies. Telomeres, at the side of the enzyme telomerase, permit most cancers cells to keep up their proliferative capability. Nevertheless, THIO is a modified nucleotide that induces telomerase-dependent alterations in telomeric DNA, triggering DNA harm responses and resulting in selective most cancers cell dying. Moreover, THIO-damaged telomeric fragments accumulate in cytosolic micronuclei, activating each innate and adaptive immune responses.
In keeping with earlier analysis, preclinical research have demonstrated that sequential remedy with THIO, adopted by PD-(L)1 inhibitors, results in profound and sustained tumor regression in superior most cancers fashions. This impact is attributed to the induction of cancer-specific immune reminiscence. Primarily based upon these earlier findings, THIO is being developed as a second-line or later remedy for people with NSCLC whose illness not response to the standard-of-care checkpoint inhibitor therapies.
As a way to consider the investigative agent, THIO-101, a multicenter, open-label, dose-finding medical trial, was designed to guage the agent’s anti-tumor exercise together with PD-(L)1 inhibition. The investigation will decide whether or not administering low doses of THIO previous to Libtayo can improve and lengthen the immune response in sufferers with superior NSCLC. This examine focuses on sufferers who beforehand didn’t reply to or developed resistance to first-line checkpoint inhibitor remedy.
The co-primary aims of the examine are to evaluate the security and tolerability of THIO as each an anticancer agent and an immune system priming activator, in addition to to guage its medical efficacy, utilizing the general response fee as the first finish level.
Therapy with THIO adopted by Libtayo has been nicely tolerated in a closely pre-treated affected person inhabitants so far.
Vitoc concluded by stating, “With our newest general survival outcomes, our outlook for potential FDA industrial approval of THIO is stronger than ever.”
For extra information on most cancers updates, analysis and training, don’t overlook to subscribe to CURE®’s newsletters right here.
